ILMN Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Illumina (NASDAQ: ILMN)
›
Illumina (NASDAQ: ILMN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 8,600 employees.
The shares were at 200.65 USD on 19 November 2026, up 65.7% over 52 weeks. Its 52-week range is 112.65 USD to 309.35 USD: the price is 35.1% below the high and 78.1% above the low.
At a market capitalisation of 30.34B USD, it trades at 34.5 times trailing earnings and 32.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, so ILMN is valued in line with them.
Illumina reports return on equity of 31.2%, an operating margin of 19.1% and revenue up 4.2% year over year.
Its debt exceeds its cash by 976.00M USD, a debt-to-equity ratio of 0.94. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 261.45 USD is 30.3% above the current price. The next earnings report is expected on 4 February 2027.